ライフサイエンスコーパス: sentinel lymph node

1 bular carcinoma, 1 invasive papilloma, and 4 sentinel lymph nodes).

2 ected by immunohistochemical analysis of the sentinel lymph node.

3 tastatic disease correctly identified in the sentinel lymph node.

4 ve nodes, 36 of whom had at least one mapped sentinel lymph node.

5 ients had successful mapping of at least one sentinel lymph node.

6 hese, 72 (79%) had metastases in the hottest sentinel lymph node.

7 malignancy, and it is useful in identifying sentinel lymph nodes.

8 Ninety-one patients (19%) had positive sentinel lymph nodes.

9 ts and 19 of 91 patients (21%) with positive sentinel lymph nodes.

10 (IQR 4.1-8.0) for the patients with positive sentinel lymph nodes.

11 Micrometastasis was detected in 1 of 5 sentinel lymph nodes.

12 atic system to these intramammary in-transit sentinel lymph nodes.

13 iposomes specific for lymph vessels from the sentinel lymph nodes.

14 gene expression in metastatic lesions within sentinel lymph nodes.

15 nificance of colon cancer micrometastasis in sentinel lymph nodes.

16 decreased VEGF-A would limit angiogenesis in sentinel lymph nodes.

17 he promotion of cancer metastasis beyond the sentinel lymph nodes.

18 rs that mediate their efficient transport to sentinel lymph nodes.

19 a was established, TIDC did not migrate into sentinel lymph nodes.

20 chnique's potential beyond merely localizing sentinel lymph nodes.

21 lap in tumor-involved relative to tumor-free sentinel lymph nodes.

22 In patients with negative sentinel lymph nodes, 11% developed metastases beyond th

23 B7-H3 expression was highly correlated to sentinel lymph node and overall number of lymph nodes wi

24 rtant role in promoting cancer metastasis to sentinel lymph nodes and beyond and also promotes organ

25 Association of SNTI in sentinel lymph nodes and BMM in patients with stage I to

26 isolated tumor cells and micrometastases) in sentinel lymph nodes and bone marrow micrometastases (BM

27 oma metastases in the hottest and nonhottest sentinel lymph nodes and factors that correlate with dis

28 atric patients more frequently have positive sentinel lymph nodes and increased tumor thickness, yet

29 mors with RhoA knockdown efficiently invaded sentinel lymph nodes and significantly metastasized to l

30 ignalling in the tumour microenvironment and sentinel lymph node, and convert immunosuppressive tumou

31 The mechanisms of tumor metastasis to the sentinel lymph nodes are poorly understood.

32 The primary endpoint, sensitivity of the sentinel-lymph-node-based detection of metastatic diseas

33 h nodes, 11% developed metastases beyond the sentinel lymph node basin and 3.4% recurred in the basin

34 ammation; the results clearly identified the sentinel lymph node basin and delineated the lymphatic d

35 There was a higher proportion of sentinel lymph node biopsies (SLNB) performed by high-vo

36 Digital images of sentinel lymph node biopsies from 56 patients with small

37 change in approach to patients with positive sentinel lymph node biopsies has increased the complexit

38 000-microCi dose of I methylene blue dye for sentinel lymph node biopsies.

39 ial mastectomy (PM), partial mastectomy with sentinel lymph node biopsy (PM SLNB), laparoscopic chole

40 Observations: Sentinel lymph node biopsy (SLNB) after NAC in patients

41 y lymph node assessment (ALNA) consisting of sentinel lymph node biopsy (SLNB) alone if sentinel lymp

42 oups according to axillary surgery approach: sentinel lymph node biopsy (SLNB) alone, SLNB+RLNR, axil

43 that disconcerting lymphedema rates in both sentinel lymph node biopsy (SLNB) and axillary lymph nod

44 TAD involves TLN biopsy (TLNB) and sentinel lymph node biopsy (SLNB) and was recently intro

45 oscintigraphy is standardly performed before sentinel lymph node biopsy (SLNB) for breast cancer.

46 Guidelines recommend sentinel lymph node biopsy (SLNB) for patients with clin

47 The validity of sentinel lymph node biopsy (SLNB) for T1 or T2, clinical

48 Indications for sentinel lymph node biopsy (SLNB) for thin melanoma are

49 evaluate the sensitivity and specificity of sentinel lymph node biopsy (SLNB) frozen section (FS) ex

50 Sentinel lymph node biopsy (SLNB) has become the gold st

51 after identification of nodal metastases by sentinel lymph node biopsy (SLNB) has been questioned.

52 iate clinical setting for the application of sentinel lymph node biopsy (SLNB) in the management of c

53 Sentinel lymph node biopsy (SLNB) is a newly developed m

54 Sentinel lymph node biopsy (SLNB) is an accurate, less i

55 ent as clinically localized T1 melanoma, yet sentinel lymph node biopsy (SLNB) is controversial in th

56 Sentinel lymph node biopsy (SLNB) is currently the stand

57 Sentinel lymph node biopsy (SLNB) is the standard of car

58 500, and 800 sec/mm(2)), followed by either sentinel lymph node biopsy (SLNB) or axillary lymph node

59 ing regional lymph node evaluation by either sentinel lymph node biopsy (SLNB) or complete lymph node

60 ociated with lower- and higher-than-expected sentinel lymph node biopsy (SLNB) positivity rates and w

61 It has been validated that sentinel lymph node biopsy (SLNB) shows whether a patien

62 l recurrence rates of patients who underwent sentinel lymph node biopsy (SLNB) using radiocolloid gui

63 Sentinel lymph node biopsy (SLNB) was developed to repla

64 surgical axillary evaluation, categorized as sentinel lymph node biopsy (SLNB), axillary lymph node d

65 ospective pediatric melanoma database, using sentinel lymph node biopsy (SLNB), from 1992 to 2006, id

66 Several less invasive procedures, such as sentinel lymph node biopsy (SLNB), marking axillary lymp

67 negative biopsy results underwent subsequent sentinel lymph node biopsy (SLNB), which yielded negativ

68 ntigraphy (LSG) enhances staging accuracy of sentinel lymph node biopsy (SLNB).

69 Final pathologic results (sentinel lymph node biopsy [SNB] or axillary lymph node

70 neoadjuvant chemotherapy could safely permit sentinel lymph node biopsy alone when the index node has

71 Available evidence for the role of sentinel lymph node biopsy as it applies to conjunctival

72 been done to select appropriate patients for sentinel lymph node biopsy based on multiple prognostic

73 Sentinel lymph node biopsy can be associated with delays

74 Sentinel lymph node biopsy can be performed either befor

75 Sentinel lymph node biopsy does not appear to have a sig

76 Patients who underwent thyroidectomy and sentinel lymph node biopsy for papillary thyroid cancer

77 of the studies in the past 2 years regarding sentinel lymph node biopsy have been concerned with iden

78 Lymphatic mapping and sentinel lymph node biopsy have been established as defi

79 review suggested that these new methods for sentinel lymph node biopsy have clinical potential but g

80 Although details of methods for sentinel lymph node biopsy have yet to be standardised,

81 d in the decision about whether to perform a sentinel lymph node biopsy in 16% of patients (67 of 420

82 ce for the efficacy of lymphatic mapping and sentinel lymph node biopsy in predicting prognosis, redu

83 metastatic spread undermines the utility of sentinel lymph node biopsy in this condition.

84 It is now well established that sentinel lymph node biopsy is a powerful test to predict

85 Sentinel lymph node biopsy is a promising procedure in p

86 Sentinel lymph node biopsy is a reasonable alternative t

87 Sentinel lymph node biopsy is performed as a standard pr

88 t findings, it seems reasonable to recommend sentinel lymph node biopsy or at least strict regional l

89 Therefore, it may be reasonable to consider sentinel lymph node biopsy or close nodal surveillance a

90 It may therefore be reasonable to consider a sentinel lymph node biopsy or strict regional lymph node

91 Results Exercise and physical activity and sentinel lymph node biopsy reduce risk, and overweight a

92 s biopsy techniques could potentially render sentinel lymph node biopsy redundant in the future.

93 ecurrence of melanoma (16%) after a negative sentinel lymph node biopsy result was similar to that in

94 eased risk of recurrence, despite a negative sentinel lymph node biopsy result.

95 ematic review to assess three techniques for sentinel lymph node biopsy that are not radioisotope dep

96 Sentinel lymph node biopsy use and 5-year cumulative inc

97 Sentinel lymph node biopsy was a possible option for 9/2

98 Sentinel lymph node biopsy was adopted for the staging o

99 A sentinel lymph node biopsy was performed in 23.3% of the

100 Sentinel lymph node biopsy was performed in 73.7% of whi

101 Sentinel lymph node biopsy was performed using an increa

102 Sentinel lymph node biopsy will not identify metastases

103 inically and radiologically normal axilla is sentinel lymph node biopsy with a radioisotope and blue

104 One patient had a sentinel lymph node biopsy, and 8 patients underwent hea

105 underwent intraoperative lymphatic mapping, sentinel lymph node biopsy, and inguinal femoral lymphad

106 left shoulder underwent wide local excision, sentinel lymph node biopsy, and lymph node dissection.

107 al hernia repair, partial mastectomy without sentinel lymph node biopsy, and partial mastectomy with

108 ry nodal burden, deselection of patients for sentinel lymph node biopsy, and provision of radiotherap

109 ng the appropriate selection of patients for sentinel lymph node biopsy, especially among patients wi

110 ographic characteristics, trends in usage of sentinel lymph node biopsy, rates of local and distant r

111 With the advent of sentinel lymph node biopsy, surgical methods for accurat

112 Most treatments, including sentinel lymph node biopsy, systemic therapy with taxane

113 With the advent of sentinel lymph node biopsy, the axilla can be accurately

114 e of adjuvant radiotherapy and the timing of sentinel lymph node biopsy.

115 a left lumpectomy with seed localization and sentinel lymph node biopsy.

116 mph node biopsy, and partial mastectomy with sentinel lymph node biopsy.

117 All patients underwent sentinel lymph node biopsy; completion lymphadenectomy w

118 ymph-node biopsy plus axillary dissection or sentinel-lymph-node biopsy alone.

119 ngoing clinical trials will evaluate whether sentinel-lymph-node biopsy can be avoided altogether in

120 section for staging has now been replaced by sentinel-lymph-node biopsy for patients with clinically

121 Sentinel-lymph-node biopsy has been embraced as a standa

122 Sentinel-lymph-node biopsy is associated with increased

123 andomly assigned women with breast cancer to sentinel-lymph-node biopsy plus axillary dissection or s

124 Refinement of the sentinel-lymph-node biopsy technique might overcome the

125 not only the indications and techniques for sentinel-lymph-node biopsy, but also lymph-node sampling

126 t (CTCL, melanoma) and nonmalignant skin and sentinel lymph nodes but not in his prostate.

127 n was assessed in primary tumors and matched sentinel lymph nodes by a quantitative real-time PCR ass

128 Negative sentinel lymph nodes (by haematoxylin and eosin staining

129 proved survival for patients with a positive sentinel lymph node compared with patients with clinical

130 None of the three sentinel lymph nodes contained metastatic carcinoma.

131 no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing metastases, 10-year over

132 no palpable axillary adenopathy, and 1 or 2 sentinel lymph nodes containing metastases.

133 s with tumor present, but not in the hottest sentinel lymph node, counts ranged from 26% to 97% of th

134 existing nonratiometric protease sensors and sentinel lymph node detection methods, which give no inf

135 ncordance of preoperative and intraoperative sentinel lymph node detection rates.

136 Sentinel lymph node dissection (SLND) accurately identif

137 s treated with breast-conserving therapy and sentinel lymph node dissection (SLND) alone without axil

138 to axillary lymph node dissection (ALND) or sentinel lymph node dissection (SLND) alone.

139 ed axillary dissection (TAD), which includes sentinel lymph node dissection (SLND) and selective loca

140 Sentinel lymph node dissection (SLND) has eliminated the

141 Marked variations in sentinel lymph node dissection (SLND) technique have bee

142 r overall survival for patients treated with sentinel lymph node dissection alone was noninferior to

143 ds from all patients who underwent selective sentinel lymph node dissection at the UCSF Melanoma Cent

144 the study a ureteral injury incurred during sentinel-lymph-node dissection.

145 aining both the ear and upper extremity, and sentinel lymph nodes draining different anatomic locatio

146 pecific fluorescent probe (MFP) to visualize sentinel lymph nodes during surgery, highlighting abnorm

147 duces expansion of lymphatic networks within sentinel lymph nodes, even before the onset of metastasi

148 Sentinel lymph node excision (SLNE) is considered the mo

149 actice gap exists in the surgical removal of sentinel lymph nodes, from removal of only the most radi

150 The sentinel lymph node hypothesis states that the pathologi

151 patients regarding the appropriate use of a sentinel lymph node identification and sampling procedur

152 hesia, is a safe and effective technique for sentinel lymph node identification in breast cancer pati

153 Use of sentinel-lymph-node identification has been extended to

154 planned procedures, and 418 had at least one sentinel lymph node identified.

155 INTERPRETATION: Sentinel lymph nodes identified with indocyanine green h

156 Homing of melanoma exosomes to sentinel lymph nodes imposes synchronized molecular sign

157 ence and outcomes of intramammary in-transit sentinel lymph nodes (IMSLN) from primary malignant mela

158 Tc99 is practical for the identification of sentinel lymph node in breast cancer.

159 Many of the published controversies about sentinel lymph nodes in breast cancer can be resolved by

160 Identification of sentinel lymph nodes in breast cancer is a combination o

161 Sentinel lymph nodes in breast carcinoma can be falsely

162 ific marker for clinical staging of cervical sentinel lymph nodes in head and neck SCC.

163 e intraoperative visualization of tumors and sentinel lymph nodes in real-time without disrupting nor

164 d tracer for the highly sensitive imaging of sentinel lymph nodes in solid tumor staging.

165 For selected patients with limited sentinel-lymph-node involvement, completion axillary-lym

166 d for detection and targeted excision of the sentinel lymph node is preoperative lymphoscintigraphy w

167 ians are looking for nonradioactive dyes for sentinel lymph node labeling.

168 number of melanocytes at both the proximal (sentinel) lymph node (LN) and the distal LN from the inj

169 In cancer patients, visual identification of sentinel lymph nodes (LNs) is achieved by the injection

170 In cancer patients, metastasis of tumors to sentinel lymph nodes (LNs) predicts disease progression

171 ver, overexpression of Adm in tumors induced sentinel lymph node lymphangiogenesis and led to an incr

172 VEGF-A-overexpressing primary tumors induced sentinel lymph node lymphangiogenesis.

173 examples of their applications ranging from sentinel lymph node mapping and tumor imaging to long-te

174 )P(1-x)/InP/ZnSe were successfully used in a sentinel lymph node mapping experiment.

175 junct use of NIRF-ICG for (a) intraoperative sentinel lymph node mapping for cancer staging, (b) vide

176 se of the GAINS to guide tumor resection and sentinel lymph node mapping promises to improve surgical

177 aspiration from the iliac crests and in vivo sentinel lymph node mapping were performed during open s

178 blue dye (specifically Lymphazurin, used for sentinel lymph node mapping).

179 D conjugates have been used successfully for sentinel lymph node mapping, tumor targeting, tumor angi

180 sensitivity and negative predictive value of sentinel-lymph-node mapping compared with the gold stand

181 cervical injection of indocyanine green and sentinel-lymph-node mapping followed by pelvic lymphaden

182 Sentinel-lymph-node mapping has been advocated as an alt

183 s with node-positive disease with successful sentinel-lymph-node mapping who had metastatic disease c

184 Sentinel-lymph-node mapping with complete pelvic lymphad

185 gate how the presence of neoplastic cells in sentinel lymph nodes may trigger pathways associated wit

186 FAM-labeled UNO (FAM-UNO) homed to tumor and sentinel lymph node MEMs in different cancer models: 4T1

187 he 10-year overall survival of patients with sentinel lymph node metastases treated with breast-conse

188 but enables the direct PET visualization of sentinel lymph node metastases, eliminating the need for

189 sentinel lymph node, presence or absence of sentinel lymph node metastases, primary tumor characteri

190 ts, heparanase expression is associated with sentinel lymph node metastases.

191 phadenectomy was performed for patients with sentinel lymph node metastasis.

192 Despite frequent involvement of the sentinel lymph nodes, most cases have an uneventful clin

193 3, 2.2-cm invasive ductal carcinoma that is sentinel lymph node negative, estrogen receptor positive

194 Paraffin-embedded tissue blocks of sentinel lymph nodes obtained from patients with patholo

195 Nodal metastases were identified in the sentinel lymph nodes of 35 (97%) of these 36 patients, y

196 nd mortality, whether present in the hottest sentinel lymph node or not.

197 The number of positive sentinel lymph nodes per patient was significantly highe

198 In the SPECT/CT cohort, more sentinel lymph nodes per patient were detected than in t

199 gh ALND may be safely avoided in a subset of sentinel lymph node positive, Z0011-eligible patients, o

200 ation may improve treatment of patients with sentinel lymph node-positive melanoma.

201 I melanoma, either via clinical detection or sentinel lymph node positivity, were eligible for enroll

202 pubertal patients had a higher percentage of sentinel lymph node positivity.

203 odes removed, technetium-99m counts for each sentinel lymph node, presence or absence of sentinel lym

204 cans decreased by an average of 36%, whereas sentinel lymph-node procedures decreased by 45%, lung sc

205 r lymphatics-mediated melanoma metastasis to sentinel lymph node prompted by tumor-derived epidermal

206 ate methods for intraoperative assessment of sentinel lymph nodes remain a clinical priority.

207 However, sentinel lymph node removal does not necessarily extend

208 The proper evaluation of sentinel lymph nodes requires histologic and immunohisto

209 cutive patients with cutaneous melanoma with sentinel lymph nodes resected from January 5, 2004, to J

210 Sentinel lymph node resection (SNR) may reduce morbidity

211 istopathology following surgical excision of sentinel lymph node(s), which is an invasive, time consu

212 Sentinel lymph node sampling is now accepted as the stan

213 Sentinel lymph nodes set the stance of the immune system

214 include: noninvasive imaging of the breast, sentinel lymph nodes, skin, thyroid, eye, prostate (tran

215 nd abdomen in a large group of patients with sentinel lymph node (SLN) -positive melanoma.

216 In breast cancer, sentinel lymph node (SLN) biopsy allows the routine perf

217 an 20% of patients with melanoma who undergo sentinel lymph node (SLN) biopsy based on American Socie

218 Sentinel lymph node (SLN) biopsy has shown great utility

219 may affect the false negative (FN) rate for sentinel lymph node (SLN) biopsy in breast cancer.

220 lmanocept is a novel radiopharmaceutical for sentinel lymph node (SLN) biopsy in breast cancer.

221 ety of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) biopsy in melanoma.

222 uideline on the use of lymphatic mapping and sentinel lymph node (SLN) biopsy in staging patients wit

223 To address this potential overtreatment, sentinel lymph node (SLN) biopsy is currently being eval

224 Sentinel lymph node (SLN) biopsy provides a textbook exa

225 e recent advancements and refinements of the sentinel lymph node (SLN) biopsy technique in breast can

226 Sentinel lymph node (SLN) biopsy was adopted for the sta

227 Wide excision and sentinel lymph node (SLN) biopsy was performed in all pa

228 There is no consensus regarding the need for sentinel lymph node (SLN) biopsy when regression is pres

229 utine examination of draining lymph nodes by sentinel lymph node (SLN) biopsy, the most important pre

230 ramatically changed with the introduction of sentinel lymph node (SLN) biopsy.

231 (CLND) for patients with melanoma staged by sentinel lymph node (SLN) biopsy.

232 lymphoscintigraphy on overall and bilateral sentinel lymph node (SLN) detection in cervical cancer p

233 tivariate analysis, patients with a positive sentinel lymph node (SLN) had significantly reduced mela

234 ately 17%, for which failure to identify the sentinel lymph node (SLN) is a major cause.

235 ard of care for patients with a positive (+) sentinel lymph node (SLN) is axillary dissection; howeve

236 rovide convenient and accurate targeting for sentinel lymph node (SLN) mapping during robotic-assiste

237 multimodality SPECT/MRI contrast agents for sentinel lymph node (SLN) mapping in vivo.

238 in patients with truncal melanoma undergoing sentinel lymph node (SLN) mapping.

239 outcomes of patients with melanoma who have sentinel lymph node (SLN) metastases can be highly varia

240 Women without sentinel lymph node (SLN) metastases should not receive

241 Conclusion Women without sentinel lymph node (SLN) metastases should not receive

242 odds ratios-to calculate the probability of sentinel lymph node (SLN) metastasis for a specific pati

243 nal study to determine factors predictive of sentinel lymph node (SLN) metastasis in thin melanoma.

244 Sentinel lymph node (SLN) metastasis is the first step i

245 Sentinel lymph node (SLN) metastasis size is an importan

246 BACKGROUND AND Sentinel lymph node (SLN) metastasis size is an importan

247 of presence or absence of various factors on sentinel lymph node (SLN) metastasis was assessed using

248 s from 65 patients undergoing resection with sentinel lymph node (SLN) or level I and II ALN dissecti

249 The principal role of sentinel lymph node (SLN) sampling and ultrastaging in c

250 ported a 12.6% false-negative rate (FNR) for sentinel lymph node (SLN) surgery after neoadjuvant chem

251 ed a false-negative rate (FNR) of 12.6% with sentinel lymph node (SLN) surgery after neoadjuvant chem

252 Sentinel lymph node (SLN) surgery provides reliable noda

253 scopic surgery, the accuracy of the isotopic sentinel lymph node (SLN) technique correlated with hype

254 An accurate, intraoperative sentinel lymph node (SLN) test could decrease delayed ax

255 ned to identify 1,256 with metastases in the sentinel lymph node (SLN).

256 correlate with the probability of a positive sentinel lymph node (SLN).

257 ion (ALND) would enable surgeons to identify sentinel lymph nodes (SLN).

258 Sentinel-lymph-node (SLN) mapping and biopsy maintains s

259 se of the B-32 trial is to establish whether sentinel-lymph-node (SLN) resection can achieve the same

260 Sentinel-lymph-node (SLN) surgery was designed to minimi

261 Immunochemical staining of sentinel lymph nodes (SLNs) and bone marrow identifies b

262 detect the fluorescent signal emanating from sentinel lymph nodes (SLNs) approximately 2 d after inje

263 0 or T2N0 breast cancer with 1 or 2 positive sentinel lymph nodes (SLNs) are recommended to undergo a

264 for the selective assessment of nonenlarged sentinel lymph nodes (SLNs) for diagnosing metastases in

265 atients with breast cancer metastasis to the sentinel lymph nodes (SLNs) generally undergo completion

266 h cT1-2N0 breast cancers and 1 to 2 involved sentinel lymph nodes (SLNs) having breast-conserving the

267 ratins (CK) is common practice in evaluating sentinel lymph nodes (SLNs) in patients with breast carc

268 etastases (clip-containing nodes) as well as sentinel lymph nodes (SLNs) may provide more accurate as

269 gional recurrence for patients with positive sentinel lymph nodes (SLNs) randomized either to axillar

270 f sentinel lymph node biopsy (SLNB) alone if sentinel lymph nodes (SLNs) were negative, SLNB with axi

271 rall survival between patients with positive sentinel lymph nodes (SLNs) who did and did not undergo

272 with breast cancer with one to two positive sentinel lymph nodes (SLNs) who undergo lumpectomy, radi

273 asured immune responses in the treated skin, sentinel lymph nodes (SLNs), and peripheral blood.

274 SLNB correlates with the number of resected sentinel lymph nodes (SLNs), our primary end point was t

275 nt part of the mapping and identification of sentinel lymph nodes (SLNs).

276 termine whether lymphoscintigraphy (LSG) for sentinel lymph node (SNL) mapping in a woman with a brea

277 Sentinel lymph node specimens (hematoxylin-eosin negativ

278 Tumor thickness and sentinel lymph node status are the most important progno

279 Sentinel lymph node studies, positron emission tomograph

280 , a prospective, multicenter study assessing sentinel lymph node surgery after neoadjuvant chemothera

281 Sentinel lymph node surgery using both blue dye (isosulf

282 melanomas, suggesting their applicability to sentinel lymph node-targeted drug delivery.

283 showed significantly higher accumulation in sentinel lymph nodes than a control peptide.

284 Once the metastatic cells arrived at the sentinel lymph nodes, the extent of lymphangiogenesis at

285 macrophages and/or dendritic cells) in human sentinel lymph node tissues.

286 portance, in mice with metastasis-containing sentinel lymph nodes, tumors that expressed VEGF-C were

287 All sentinel lymph nodes underwent multilevel sectioning and

288 acity to delineate metastases and to map the sentinel lymph nodes via tandem PET-computed tomography

289 The sentinel lymph node was evaluated in 11 patients, result

290 urvival in patients with at least 1 positive sentinel lymph node was less than 55%.

291 Histologic ultra staging of the sentinel lymph node was prescribed.

292 Patients who had mapping of at least one sentinel lymph node were included in the primary analysi

293 A total of 1575 sentinel lymph nodes were analyzed in 475 patients.

294 d from patients with pathologically negative sentinel lymph nodes were centrally evaluated for occult

295 The margins were clear, and three sentinel lymph nodes were negative for metastasis.

296 Sentinel lymph nodes were successfully detected in all p

297 ar-infrared dye show that the GAINS detected sentinel lymph nodes with 100% sensitivity.

298 method on an open-source dataset of WSI from sentinel lymph nodes with breast cancer metastases, CAME

299 e operative protocol led to resection of all sentinel lymph nodes with radioactivity greater than 10%

300 Removing only the hottest sentinel lymph node would have led to false-negative res